How Analysts Feel About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)?





August 29, 2017 – By Darrin Black







Investors sentiment decreased to 0.77 in Q4 2016. Its down 0.25, from 1.02 in 2016Q3. It is negative, as 64 investors sold Alnylam Pharmaceuticals, Inc. shares while 65 reduced holdings. 35 funds opened positions while 64 raised stakes. 78.05 million shares or 3.80% more from 75.19 million shares in 2016Q3 were reported.
Winslow Evans Crocker has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). California State Teachers Retirement Sys reported 156,090 shares. Moreover, Jane Street Grp Lc has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 44,616 shares. Moreover, Blue Ridge Capital Ltd Liability Corporation has 0.62% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1.32 million shares. Citigroup has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Tocqueville Asset Mngmt Lp owns 17,005 shares for 0.01% of their portfolio. Advsr Asset Inc reported 22,918 shares or 0.01% of all its holdings. Opus Point Ptnrs reported 2.65% stake. Point72 Asia (Hong Kong) has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Vigilant Capital Management Ltd Liability reported 200 shares. Plante Moran Advisors Llc owns 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 54 shares. Morgan Stanley reported 812,184 shares. Kcg reported 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 947 were reported by Kbc Grp Incorporated Nv. Bancshares Of Montreal Can has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Since May 15, 2017, it had 2 insider purchases, and 3 selling transactions for $17.81 million activity. Another trade for 297,501 shares valued at $21.38M was made by Sanofi on Wednesday, May 31. On Tuesday, May 16 the insider Mason Michael sold $656,250. KEATING LAURIE bought $751,502 worth of stock or 11,500 shares.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 21 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 12 have Buy rating, 0 Sell and 9 Hold. Therefore 57% are positive. Alnylam Pharmaceuticals had 55 analyst reports since August 7, 2015 according to SRatingsIntel. On Thursday, October 6 the stock rating was maintained by Goldman Sachs with “Neutral”. The stock has “Buy” rating by Needham on Monday, June 26. On Friday, July 7 the stock rating was maintained by Chardan Capital Markets with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Monday, July 10 by Needham. As per Thursday, August 10, the company rating was maintained by BMO Capital Markets. The firm earned “Buy” rating on Thursday, August 10 by Chardan Capital Markets. The firm earned “Overweight” rating on Friday, August 5 by JP Morgan. The firm has “Buy” rating by Chardan Capital Markets given on Monday, June 12. The rating was maintained by BMO Capital Markets with “Buy” on Monday, June 26. On Saturday, August 22 the stock rating was downgraded by TheStreet to “Hold”. Below is a list of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) latest ratings and price target changes.

24/08/2017 Broker: Jefferies Rating: Buy New Target: $102.0 Maintain
11/08/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $56.0000 Maintain
10/08/2017 Broker: Chardan Capital Markets Rating: Buy Maintain
10/08/2017 Broker: BMO Capital Markets Rating: Buy New Target: $105.0000 Maintain
10/08/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $46 New Target: $50 Maintain
10/08/2017 Broker: Barclays Capital Rating: Hold New Target: $80.0000
04/08/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0000 Maintain
27/07/2017 Broker: Bernstein Rating: Outperform New Target: $99 Initiates Coverage On
17/07/2017 Broker: Ladenburg Rating: Buy New Target: $90.0000
11/07/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0000 Maintain

The stock decreased 0.82% or $0.68 during the last trading session, reaching $82.52. About 665,285 shares traded or 0.03% up from the average. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since August 29, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $7.57 billion. The Firm is engaged in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Alnylam and The Medicines Company’s inclisiran shows significant treatment …” on August 28, 2017, also Zacks.com with their article: “Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season August …” published on August 08, 2017, Fool.com published: “Alnylam Pharmaceuticals results: The only number that really matters” on August 14, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Alnylam: Q3 Catalysts Play” published on August 23, 2017 as well as Seekingalpha.com‘s news article titled: “Alnylam Pharmaceuticals (ALNY) Q2 2017 Results – Earnings Call Transcript” with publication date: August 10, 2017.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *

*

ten + fourteen =